July's most-read articles: Deploying artificial intelligence in GI diseases; Ashley McEvoy on charting the future of J&J medtech; Sheba Medical seeks global collaboration for digital innovation; Luna Health pioneers automatic, night-time insulin delivery; SymPhysis Medical's patient-centric approach to pleural effusion.
The top five MedTech Strategist July articles.
Subscribers, click through to read the full articles. Non-subscribers, take advantage of our free trial offer.
Artificial intelligence has emerged as a valuable tool in diagnostic imaging, where machine-learning algorithms applied to image-based scans are helping physicians rapidly and accurately detect and diagnose diseases such as diabetic retinopathy, cancer, and stroke. Now, AI is branching into video endoscopy and could help level the playing field for patients with a number of GI disorders. Among the companies leading the way are Medtronic, Iterative Scopes, and Odin Vision.
At one of this year’s Stanford Biodesign Innovator’s Workbench programs, Ashley McEvoy, head of J&J’s MedTech business, talked about the current state of the company’s medical device businesses, the impact of the COVID pandemic, and what the future holds for J&J MedTech.
Fresh out of stealth mode, Luna Health, founded by three diabetes device stalwarts—Sean Saint, John Sjölund, and Jon Brilliant—is preparing for a US trial of its automated insulin delivery system, a first-of-its-kind, nighttime-only on-body device that Sjölund says will make the experience of automated insulin delivery “much simpler and more accessible to many more people.”
Sheba Medical/ARC Innovation's global ambitions to build a healthcare ecosystem based on transformative collaborations and digital innovations are gaining traction overseas. In the US, the Mayo Clinic and the newly formed Chicago ARC recently signed on as partners, and Chicago ARC is raising $100 million to invest in digital and medical device start-ups.
Malignant pleural effusion is a side effect of several prevalent cancers that causes fluid to accumulate in the chest cavity, limiting the expansion of the lungs and causing breathlessness, anxiety, and chest pain. While some drainage devices exist to alleviate this condition, SymPhysis Medical has engineered the first device that patients can use autonomously, restoring independence to their lives.
Trial MyStrategist.com and unlock 7-days of exclusive subscriber-only access to the medical device industry's most trusted strategic publications: MedTech Strategist & Market Pathways. For more information on our demographics and current readership click here.